Fractyl Health (GUTS) Financials

Fractyl Health’s latest statements show a clinical-stage company that continues to invest heavily in research while generating essentially no operating revenue. The financial picture is mixed: operating expenses have moderated, but recurring losses, cash burn, negative equity and share dilution remain significant concerns.

• Operating expenses improved. Second-quarter 2026 operating expenses were $19.1 million, down from $20.8 million in the first quarter and $26.1 million in the second quarter of 2025. Research and development spending declined to $13.8 million from $15.6 million sequentially and $21.2 million a year earlier.
• Cash interest income continues to provide a modest offset. Fractyl reported $431,000 of interest and investment income in Q2 2026, while cash interest paid was $1.1 million. The company’s cash balance still provides funding for ongoing development activities, although the balance is declining.
• Capital expenditures remain limited. The company reported only $278,000 of depreciation expense in Q2 2026 and no reported property, plant and equipment purchases in the quarter. This suggests that near-term cash needs are driven primarily by research, corporate and other operating expenses rather than heavy infrastructure spending.
• Fractyl remains pre-revenue. Revenue was $0 in Q2 2026, consistent with the prior three quarters. Revenue in earlier periods was only nominal, reaching $43,000 in Q2 2024 and $3,000 in Q4 2024, so the company has not yet demonstrated a commercial revenue base.
• Quarterly losses have been volatile because of non-operating items. The company reported a $25.5 million net loss in Q2 2026 after recording a $9.2 million profit in Q1. The first-quarter result was driven by $29.4 million of other income, while Q2 included $6.9 million of other expense. These items do not appear to reflect recurring operating performance.
• Cash is declining rapidly. Cash and equivalents fell from $121.4 million in Q1 2024 to $47.1 million at June 30, 2026, including a $16.0 million decline during Q2 2026. Operating cash outflow was $15.9 million in Q2, compared with $22.5 million in Q1 and approximately $21 million to $23 million in most 2025 quarters.
• The company has persistent operating losses and no revenue cushion. Operating losses have remained near or above $20 million per quarter since 2024. Q2 2026 produced a $19.1 million operating loss and a $25.5 million net loss, or a $0.16 loss per share, despite the recent reduction in expenses.
• Shareholder equity turned negative. Total equity fell from positive $21.4 million at March 31, 2026, to negative $1.7 million at June 30 after the quarterly loss. Total liabilities of $83.6 million exceeded total assets of $82.0 million, indicating a highly leveraged balance sheet relative to the company’s asset base.
• Liquidity is weakening even though current assets exceed current liabilities. Fractyl had $49.6 million of current assets versus $15.7 million of current liabilities, but cash alone was only about three times quarterly operating cash burn in Q2. Without an improvement in cash generation or additional financing, the company may need to raise capital within several quarters.
• Share dilution has been substantial. Weighted-average basic shares increased from approximately 47.9 million in Q2 2024 to 158.6 million in Q2 2026. Historical cash inflows have frequently depended on equity issuance, which can provide funding but reduces existing shareholders’ ownership percentage and may pressure per-share value.

Overall, Fractyl’s lower research and administrative spending is a constructive development, but the company remains dependent on external capital while it has no meaningful revenue and continues to burn cash. Investors should focus on clinical progress, the timing of potential commercialization and whether management can secure funding without further substantial dilution.